WARRINGTON, Pa., Jan. 27, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) will host a conference call on Tuesday, February 1, 2011, at 10:00 AM EST. Management will provide an overview of Discovery Labs' efforts to gain U.S. Food and Drug Administration (FDA) marketing approval of Surfaxin ® for the prevention of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that a key remaining issue necessary to potentially gain FDA marketing approval for Surfaxin is to satisfy the FDA as to the validation of the fetal rabbit biological activity test (BAT), an important quality control release and stability test for Surfaxin. On January 10, 2011, Discovery Labs issued a press release announcing that the FDA had recently provided detailed, written direction regarding certain components of Discovery Labs' comprehensive pre-clinical program, which is intended to potentially satisfy the FDA as to the validation of the BAT. As indicated in that press release, in the upcoming conference call, management will provide an overview of the program and review its progress. Participants are encouraged to access this audio webcast through a live broadcast on the Company's website at www.discoverylabs.com. It is recommended that participants log onto the audio webcast at least 15 minutes prior to the call. The Internet broadcast will be available for up to 90 days after the call at the Company's website. The call in number is 866-332-5218. The international call in number is 706-679-3237. A replay of the conference call will be available two hours after the call's completion and remain available through February 8, 2011. The replay number to hear the conference call is 800-642-1687 or 706-645-9291. The passcode is 40660551. About Discovery Labs Discovery Laboratories, Inc. is a biotechnology company developing KL4 surfactant therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol and lyophilized formulations. In addition, Discovery Labs' proprietary capillary aerosolization technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.
CONTACT: John G. Cooper, President and Chief Financial Officer 215-488-9490